Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30,

Cash burn of $3.8 million in Q2 remains in line with projected quarterly range – Cash and investments are sufficient to fund operations through Q3’2026 at current cash burn rate – Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H’2025 – IDE submission for enVVe® on

Masimo ( ($MASI) ) has shared an update. On August 5, 2025, Masimo Corporation announced its financial results for the second quarter of 2025,

Launched next-generation robotaxi partnership that will see Uber deploy a minimum of 20,000 Lucid Gravity vehicles equipped with Nuro Driver (TM) Level 4 autonomy -- Expanded DreamDrive Pro functionality to add Hands-Free Drive Assist and Lane Change Assist,

The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”),